154 related articles for article (PubMed ID: 37781235)
1. Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy.
Martinez-Morilla S; Moutafi M; Fernandez AI; Jessel S; Divakar P; Wong PF; Garcia-Milian R; Schalper KA; Kluger HM; Rimm DL
Oncoimmunology; 2023; 12(1):2260618. PubMed ID: 37781235
[TBL] [Abstract][Full Text] [Related]
2. High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling.
Toki MI; Merritt CR; Wong PF; Smithy JW; Kluger HM; Syrigos KN; Ong GT; Warren SE; Beechem JM; Rimm DL
Clin Cancer Res; 2019 Sep; 25(18):5503-5512. PubMed ID: 31189645
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling.
Moutafi M; Martinez-Morilla S; Divakar P; Vathiotis I; Gavrielatou N; Aung TN; Yaghoobi V; Fernandez AI; Zugazagoitia J; Herbst RS; Schalper KA; Rimm DL
J Thorac Oncol; 2022 Aug; 17(8):991-1001. PubMed ID: 35490853
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non-Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling.
Zugazagoitia J; Gupta S; Liu Y; Fuhrman K; Gettinger S; Herbst RS; Schalper KA; Rimm DL
Clin Cancer Res; 2020 Aug; 26(16):4360-4368. PubMed ID: 32253229
[TBL] [Abstract][Full Text] [Related]
5. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
6. Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.
Moutafi MK; Molero M; Martinez Morilla S; Baena J; Vathiotis IA; Gavrielatou N; Castro-Labrador L; de Garibay GR; Adradas V; Orive D; Valencia K; Calvo A; Montuenga LM; Ponce Aix S; Schalper KA; Herbst RS; Paz-Ares L; Rimm DL; Zugazagoitia J
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002182
[TBL] [Abstract][Full Text] [Related]
7. Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma.
Wong PF; Wei W; Gupta S; Smithy JW; Zelterman D; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Jul; 7(1):194. PubMed ID: 31337426
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy.
Martinez-Morilla S; Zugazagoitia J; Wong PF; Kluger HM; Rimm DL
Oncoimmunology; 2020 Dec; 10(1):1864909. PubMed ID: 33457084
[TBL] [Abstract][Full Text] [Related]
9. Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma.
Su DG; Schoenfeld DA; Ibrahim W; Cabrejo R; Djureinovic D; Baumann R; Rimm DL; Khan SA; Halaban R; Kluger HM; Olino K; Galan A; Clune J
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519058
[TBL] [Abstract][Full Text] [Related]
10. Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry.
Martinez-Morilla S; Villarroel-Espindola F; Wong PF; Toki MI; Aung TN; Pelekanou V; Bourke-Martin B; Schalper KA; Kluger HM; Rimm DL
Clin Cancer Res; 2021 Apr; 27(7):1987-1996. PubMed ID: 33504554
[TBL] [Abstract][Full Text] [Related]
11. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
Attrill GH; Owen CN; Ahmed T; Vergara IA; Colebatch AJ; Conway JW; Nahar KJ; Thompson JF; Pires da Silva I; Carlino MS; Menzies AM; Lo S; Palendira U; Scolyer RA; Long GV; Wilmott JS
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688560
[TBL] [Abstract][Full Text] [Related]
12. Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy.
Sadeghirad H; Liu N; Monkman J; Ma N; Cheikh BB; Jhaveri N; Tan CW; Warkiani ME; Adams MN; Nguyen Q; Ladwa R; Braubach O; O'Byrne K; Davis M; Hughes BGM; Kulasinghe A
Front Immunol; 2023; 14():1135489. PubMed ID: 37153589
[TBL] [Abstract][Full Text] [Related]
13. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy.
Qin Y; Bollin K; de Macedo MP; Carapeto F; Kim KB; Roszik J; Wani KM; Reuben A; Reddy ST; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Lazar AJ; Hwu P; Patel SP
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203661
[TBL] [Abstract][Full Text] [Related]
14. Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.
Li L; Lu G; Liu Y; Gong L; Zheng X; Zheng H; Gu W; Yang L
Front Oncol; 2021; 11():658690. PubMed ID: 34150625
[TBL] [Abstract][Full Text] [Related]
15. Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients.
Kulasinghe A; Taheri T; O'Byrne K; Hughes BGM; Kenny L; Punyadeera C
Front Oncol; 2020; 10():607349. PubMed ID: 33542903
[TBL] [Abstract][Full Text] [Related]
16. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
Serratì S; Guida M; Di Fonte R; De Summa S; Strippoli S; Iacobazzi RM; Quarta A; De Risi I; Guida G; Paradiso A; Porcelli L; Azzariti A
Mol Cancer; 2022 Jan; 21(1):20. PubMed ID: 35042524
[TBL] [Abstract][Full Text] [Related]
17. Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma.
Yaseen Z; Gide TN; Conway JW; Potter AJ; Quek C; Hong AM; Long GV; Scolyer RA; Wilmott JS
Front Mol Biosci; 2022; 9():810858. PubMed ID: 35664673
[TBL] [Abstract][Full Text] [Related]
18. Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM.
Placke JM; Kimmig M; Griewank K; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Welzel J; Engel DR; Kreft S; Sucker A; Lodde G; Krefting F; Stoffels I; Klode J; Roesch A; Zimmer L; Livingstone E; Hadaschik E; Becker JC; Weichenthal M; Tasdogan A; Schadendorf D; Ugurel S
EBioMedicine; 2023 Oct; 96():104774. PubMed ID: 37660535
[TBL] [Abstract][Full Text] [Related]
19. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
20. The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy.
Puza CJ; Bressler ES; Terando AM; Howard JH; Brown MC; Hanks B; Salama AKS; Beasley GM
J Surg Res; 2019 Apr; 236():209-215. PubMed ID: 30694757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
